Isoray, Inc.: directors' dealings · United States · SEC (Form 4)

About Isoray, Inc.

Isoray, Inc. is best understood as a historically U.S.-based oncology technology company whose legacy business was built around targeted radiation delivery. For market-context purposes, it is important to note that the company was folded into the corporate transformation that led to Perspective Therapeutics, Inc., a U.S.-listed issuer whose securities have traded on U.S. exchanges in the NYSE American / NASDAQ ecosystem depending on the period and ticker history. In other words, while investors may still encounter the Isoray name in filings, insider transactions, or historical references, the economic story now sits within the broader radiopharmaceutical and precision-oncology platform that emerged after the corporate restructuring. The company’s roots date back to the early 1980s, and its historical operational base was Richland, Washington, United States, reflecting a long-standing manufacturing and regulatory footprint in medical radioactive materials. ([sec.gov](https://www.sec.gov/Archives/edgar/data/728387/000072838726000004/catx-20251231.htm?utm_source=openai)) The legacy core of Isoray was its Cesium-131 brachytherapy seed business. These implants were designed to deliver radiation directly to tumor sites while limiting dose to surrounding healthy tissue, with early commercial adoption centered on prostate cancer and broader use depending on physician preference and clinical application. From a competitive standpoint, the business occupied a niche within oncology, competing against external beam radiation, surgery, and other brachytherapy isotopes and devices. That positioning gave Isoray a differentiated clinical proposition, but it also exposed the company to adoption cycles, reimbursement dynamics, and the regulatory burden associated with radioactive medical products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/728387/000143774919019176/isr20190630_10k.htm?utm_source=openai)) The most important recent development is that the company’s profile has changed materially. In February 2023, Isoray completed a merger with Viewpoint Molecular Targeting, and shortly thereafter changed its corporate name to Perspective Therapeutics, Inc. Later, in December 2023, the company entered into an asset purchase agreement to sell substantially all commercial Cesium-131 brachytherapy assets to GT Medical Technologies, including equipment, related contracts and leases, inventory, and intellectual property. This means the legacy Isoray commercial franchise was largely divested, and the business mix shifted toward radiopharmaceuticals and precision oncology development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/728387/000072838726000004/catx-20251231.htm?utm_source=openai)) For French, Belgian, and Swiss investors, the key takeaway is that Isoray should no longer be viewed solely as a traditional medical-device or isotope-seed manufacturer. Instead, it is a U.S. health-care story marked by strategic pivot, corporate simplification of the old brachytherapy asset base, and a move toward higher-value oncology platforms. The company’s geographic presence remains primarily U.S.-centered, with historical manufacturing and headquarters links to Washington State and clinical-development activities associated with the new group structure. Recent news is therefore mostly corporate and strategic rather than commercial: merger completion, name change, and divestiture of the legacy business. That combination is highly relevant for any analysis of SEC Form 4 insider activity, because the capital allocation story is now tied to the new platform rather than the historic Cesium-131 franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/728387/000072838726000004/catx-20251231.htm?utm_source=openai))